Details of Host Protein-DME Interaction (HOSPPI)
| General Information of Drug-Metabolizing Enzyme (DME ID: DME0608) | |||||
|---|---|---|---|---|---|
| DME Name | Cytochrome P450 7B1 (CYP7B1), Homo sapiens | DME Info | |||
| UniProt ID | |||||
| EC Number | EC: 1.14.14.29 (Click to Show/Hide the Complete EC Tree) | ||||
| Lineage | Species: Homo sapiens (Click to Show/Hide the Complete Species Lineage) | ||||
| Interactome | |||||
| Disease Specific Interactions between Host Protein and DME (HOSPPI) | |||||
|---|---|---|---|---|---|
| ICD Disease Classification 02 Neoplasms | |||||
| ICD-11: 2B30 Lymphoma | Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI | ||||
| DNA methylation | |||||
| DNA methyltransferase (DNMT) | Lymphoma | Significant hypermethylation | |||
| Interaction Name | DNMT-CYP7B1 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Significant hypermethylation p-value: 7.47E-18; delta-beta: 4.23E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to significantly hyper-methylate the CYP7B1 gene, which leads to a significantly decreased expression of the drug-metabolizing enzyme Cytochrome P450 7B1. As a result, the interaction between DNMT and CYP7B1 can significantly affect the drug-metabolizing process of Cytochrome P450 7B1. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| ICD-11: 2B5F Uterine carcinosarcoma | Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI | ||||
| DNA methylation | |||||
| DNA methyltransferase (DNMT) | Uterine carcinosarcoma | Significant hypermethylation | |||
| Interaction Name | DNMT-CYP7B1 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Significant hypermethylation p-value: 2.19E-05; delta-beta: 3.91E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to significantly hyper-methylate the CYP7B1 gene, which leads to a significantly decreased expression of the drug-metabolizing enzyme Cytochrome P450 7B1. As a result, the interaction between DNMT and CYP7B1 can significantly affect the drug-metabolizing process of Cytochrome P450 7B1. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| ICD-11: 2B90 Colorectal cancer | Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI | ||||
| Non-coding RNA regulation | |||||
| hsa-miR-17-5p | Colorectal cancer | Suppression | |||
| miRBase ID | |||||
| Interaction Name | hsa-miR-17-5p--CYP7B1 regulation | [1] | |||
| Studied Cell Lines | DLD1 cell line | ||||
| Description | hsa-miR-17-5p is reported to suppress CYP7B1 mRNA translation by binding to the 3' untranslated region (3'UTR) of CYP7B1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Cytochrome P450 7B1. | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.